Adult ADHD

Attention deficit hyperactivity disorder (ADHD) is considered a common neurodevelopmental disorder. Individuals with ADHD are characterized by difficulties in attention, impulsive behaviors, and/or are overactivity. These manifestations are widely considered as the ‘core symptoms’ of ADHD. Other common challenges include deficits in cognitive performance, executive dysfunction, and dysfunctional emotional regulation.

​

While current treatments are effective in improving ADHD core symptoms, they bare significant side effects making them difficult to tolerate.

In our Phase II study conducted in the Massachusetts General Hospital (MGH) in adult ADHD patients, NRCT-101 (L-TAMS) was shown to significantly reduce core symptoms of ADHD. NRCT-101 administration also significantly improved overall function  and cognition.

NRCT-101SR was demonstrated to have a very good safety profile without significant side effects.

Late-Life Depression

It is estimated that approximately 15% of the adults in the US suffer from Major Depressive Disorder (MDD), and 13.2% are treated with antidepressants.

​

Unfortunately, the effects of current medications on older adults are considered to be minor, and they are not addressing significant comorbidities of MDD, for example cognitive impairment.

In previous clinical trials NRCT-101SR was shown to improve emotional regulation and cognition in older adults.

Understanding the needs of older adults suffering from depression, We are currently in preparations for a late-phase clinical trial to test the efficacy of NRCT-101SR in late-life depression.

Early Alzheimer's Disease

Current medications for Alzheimer’s Disease are approved specifically for dementia-stage AD.  In recent years, there has been a growing movement to develop drugs to target pre-dementia AD.

Identifying people who are at risk and treating them before they decline to dementia is important and will have a greater impact on quality of life for these people.

​

For treating Prodromal AD, the bar for safety is extremely high. MMFS has an excellent safety profile and is ideally suited for prevention. 

In targeting Prodromal AD, we have focused on elderly who have a high risk for developing dementia – those with mild cognitive impairment, mild behavioral impairment, and sleep disorder.

​​

Our Phase IIb trial is currently in preparation.